Micron Biomedical

Micron Biomedical’s CEO, Steven Damon, and CFO, Idean M., are en route to Stockholm, Sweden to attend #BioEurope 2024. This year, the event celebrates its 30th anniversary of facilitating partnerships by bringing together more than 5,000 delegates, 2,500 companies and representation from more than 65 countries. If you’re among this year’s attendees, please reach out on the partnering app to make a plan to connect!

Imagine the convenience of receiving previously injectable-only medications directly to you, no matter where you call home. That’s a vision we’re advancing with needle-free technology that allows painless, self-administration of vaccines and therapeutics. Learn more about the future of drug delivery technology at: https://lnkd.in/gTY-g4Ta

The opportunity to disrupt healthcare with medicines and vaccines that can be delivered and stored with less to no refrigeration, without the need for clinicians (and mass vaccination sites or doctor visits) could be life-changing and life saving! So excited that this session getting one step closer to getting on the big stage at #SXSW and thrilled to be collaborating with these change-makers!

Exciting news--a #SXSW 2025 panel nomination featuring Micron Biomedical’s Steven Damon, alongside public health activist, Dr. Rick Bright; global health pioneer, Dr. Seth Berkley; and the One Health Institute at UC Davis’ Dr. marcela uhart is one step closer to making it on the main stage at one of the country’s most popular idea exchanges, #SXSW.   We’re thrilled to learn this week that the SXSW organizers have identified this session as a top 300 pick out of more than 3,400 nominated topics about “everything from the newest weight loss drugs to the impact of differentiated stem cell technology on neuroscience, as well as the solutions and tools that provide better outcomes for patients everywhere.” With H5N1 now spreading rapidly in cows and emerging more frequently in farm workers, it is more critical than ever to have open dialogues between epidemiologists, veterinarians, public health ambassadors and the private sector.  Thank you to all who supported this panel by “upvoting” over the summer.

Micron Biomedical EVP, and Head of Technical Operations, Sebastien Henry, is speaking today at the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms 2024 PHARMSCI 360 in Salt Lake City to discuss advanced drug delivery technologies and describe how Micron's needle-free technology can expand access to vital medicines and enhance human health. We are excited to be part of this important symposium, share details on our next-generation technology, and discuss takeaways from our #measles and rubella clinical trial. 

We are sharing photos from the 2024 BWB Awards, where Micron Biomedical won the #Biotech #Innovation Award—an exclusive accolade in recognition of conceiving a new or advancing biopharmaceutical product, manufacturing process or ground-breaking technology that yielded significant results. Informa Connect put on a fabulous program, hosted by Olympic medalist and TEDX speaker, Chaunte Lowe, OLY, which included talented musicians, entertainment and even an aerial acrobatic performance. Thank you, BWB Awards and parters for recognizing Micron Biomedical and treating us to this special evening. 

Micron Biomedical is excited to attend HLTH USA 2024, the preeminent event for healthcare and wellness innovation. HLTH is an opportunity to strengthen partnerships and gain insights from other movers and shakers dedicated to advancing disruptive technologies and transforming the future of healthcare innovation. If you will be in Las Vegas next week, let’s connect at HLTH 2024!

Conventional fertility treatments are daunting for many women and couples, with the need for multiple daily injections, many requiring drug reconstitution. Imagine your fertility treatments delivered in a convenient and painless “button” format that can be easily self-administered. At Micron Biomedical, we are envisioning a way to simplify drug delivery and make treatments as seamless, painless and efficient as possible--with a range of applications across multiple #therapeutic and #vaccine classes. Learn more about our dissolvable microarray technology here: https://lnkd.in/gKqNfqXf

Organizations like Global Center for Medical Innovation - GCMI are integral to biotech innovation and allow early-stage companies to test and incubate potentially groundbreaking ideas in an increasingly competitive climate. GCMI’s early and ongoing support of Micron Biomedical allowed us to perfect and trial a potentially life-saving technology that has been heralded as game changing in humanitarian settings. Together, we are changing the world for the better. In this article, Micron Biomedical CEO, Steven Damon, stresses “this is why we innovate. This is why we work together. This is why leaders invest in each other and foster innovation with high commercial potential. To make the world a better, healthier place.” Thank you, GCMI, for believing in our vision and extending us the resources to succeed. 

We are imagining, and working towards a future where measles are a thing of the past. Micron’s unique needle-free microarray technology is thermostable, produces no sharps waste, and can be self-administered or administered by a non-clinical caregiver or parent – enabling life saving vaccinations to reach all corners of the globe without a sophisticated cold chain. In practice, Micron Biomedical is leading the world on needle-free vaccinations of children as young as 9 months old in remote locations and our clinical data has been published in the The Lancet Medical Journal. A future free of #measles is within reach with innovation and coordination. See how here: https://lnkd.in/gyK5nAgU